The compositions have a characteristic in vitro release profile.doi:US20040185095 A1Hanshermann FrankePeter LennartzUSUS20040185095 May 15, 2003 Sep 23, 2004 Hanshermann Franke Pharmaceutical composition containing oxcarbazepine and having a controlled active substance release...
the parent molecule carbamazepine as a template, and to produce a drug as effective as carbamazepine, but with an improved side-effect profile. A key difference between the two drugs is that oxcarbazepine unlike carbamazepine is not metabolized to an epoxide derivative[7]. As the epoxide is resp...
Substance Name Oxcarbazepine CAS Registry Number 28721-07-5 Drug Class Breast Feeding Lactation Milk, Human Anticonvulsants Disclaimer:Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related...
Evidence indicates that CBZ is better tolerated with the controlled-release formulation (CBZ-CR), as suggested by studies conducted in the elderly population. For example, in a multicenter study comparing CBZ-IR with lamotrigine, the latter was significantly better tolerated than CBZ-IR [29]; ...
Ventilation System:In general, dilution ventilation is a satisfactory health hazard control for this substance. However, if conditions of use create discomfort to the worker, a local exhaust system should be considered. Personal Respirators (NIOSH Approved):Not expected to require personal respirator ...
The invention relates to pharmaceutical compositions, particularly oral compositions, containing an effective content of oxcarbazepine and having a delayed active substance release. The compounds have a characteristic in-vitro release profile.FRANKE HANSHERMANN...
Oxcarbazepine is structurally a derivative of carbamazepine; used for the treatment of partial seizures in epileptic children and adults[1]. Compared with carbamazepine, it contains an extra oxygen atom to the benzylcarboxamide group, reducing the impact on the liver of metabolizing the drug, and al...
4. The said method for chemical synthesis of oxcarbazepine in Claim 1, the ratio of amount of substance between HCl in the said hydrochloric acid and 5-cyano-10-nitro-5H-dibenz[b,f]azepine (III) is 0.8 to 3.0:1. 5. The said method for chemical synthesis of oxcarbazepine in Claim 2,...